Back to Resource Library
01:01:11
Webinar Description:
Investors have access to large amounts of clinical and market data, however they don’t always have visibility to the details of developing, manufacturing, and distributing autologous cell therapies.
This webinar considers a variety of perspectives, from academic clinical center manufacturing through to large scale biopharma deployment. The speakers will discuss their cell therapy journey, areas where the industry is making real progress and areas that are lagging. The audience should come away from this webinar with a greater understanding of autologous process details and where to focus effort when executing diligence in this field.
Autologous Cell TherapyWebinar 1 of the ISCT I to I Due Diligence Roadmap Series Presented by the Business Development and Finance Committee
Co-Chaired By:
Phil Vanek, PhDISCT Business Development & Finance Committee MemberChief Technology Officer,GammaBioUnited States
Maria Fardis, PhDVenture Partner,Frazier Life Sciences United States
Jim Faulkner, PhDVenture Partner,AppleTree Partners (ATP)United Kingdom
Rodney L Rietze, PhDCEO,iVexSolUnited States
Isabelle Rivière, PhDDirector, Cell Therapy and Cell Engineering Facility,Memorial Sloan-Kettering Cancer CenterUnited States